NASDAQ:OMCL Omnicell (OMCL) Stock Price, News & Analysis $35.01 -0.34 (-0.96%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$34.90 -0.11 (-0.33%) As of 03/28/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Omnicell Stock (NASDAQ:OMCL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Omnicell alerts:Sign Up Key Stats Today's Range$33.89▼$35.3150-Day Range$32.28▼$45.3152-Week Range$25.12▼$55.75Volume808,201 shsAverage Volume518,911 shsMarket Capitalization$1.64 billionP/E Ratio129.67Dividend YieldN/APrice Target$51.00Consensus RatingHold Company OverviewOmnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.Read More… Remove Ads Omnicell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreOMCL MarketRank™: Omnicell scored higher than 61% of companies evaluated by MarketBeat, and ranked 405th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingOmnicell has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageOmnicell has only been the subject of 4 research reports in the past 90 days.Read more about Omnicell's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth13.76% Earnings GrowthEarnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is 129.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is 129.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.60.Price to Earnings Growth RatioOmnicell has a PEG Ratio of 7.53. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Omnicell's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.64% of the float of Omnicell has been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 10.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.64% of the float of Omnicell has been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 10.38%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.58 News SentimentOmnicell has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Omnicell this week, compared to 5 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.64% of the stock of Omnicell is held by insiders.Percentage Held by Institutions97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omnicell's insider trading history. Receive OMCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter. Email Address OMCL Stock News HeadlinesIs The Market Rewarding Omnicell, Inc. (NASDAQ:OMCL) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?March 29 at 10:02 AM | finance.yahoo.comOmnicell appoints Perry Genova as new CTOMarch 26, 2025 | investing.comWhy Buffett and 100 members of Congress are Piling into this One InvestmentWhile everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.March 31, 2025 | Behind the Markets (Ad)StockNews.com Downgrades Omnicell (NASDAQ:OMCL) to HoldMarch 26, 2025 | americanbankingnews.comOmnicell Welcomes Perry A. Genova, PhD, as Chief Technology OfficerMarch 24, 2025 | businesswire.comOmnicell (NASDAQ:OMCL) Price Target Lowered to $36.00 at JPMorgan Chase & Co.March 23, 2025 | americanbankingnews.comOmnicell price target lowered to $36 from $44 at JPMorganMarch 21, 2025 | markets.businessinsider.comOmnicell, Inc. (OMCL) Stock ForecastsMarch 20, 2025 | ca.finance.yahoo.comSee More Headlines OMCL Stock Analysis - Frequently Asked Questions How have OMCL shares performed this year? Omnicell's stock was trading at $44.52 at the start of the year. Since then, OMCL shares have decreased by 21.4% and is now trading at $35.01. View the best growth stocks for 2025 here. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings results on Thursday, February, 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by $0.12. Omnicell had a trailing twelve-month return on equity of 3.82% and a net margin of 1.13%. Does Omnicell have any subsidiaries? The following companies are subsidiaries of Omnicell: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others. Who are Omnicell's major shareholders? Top institutional investors of Omnicell include Vanguard Group Inc. (12.01%), Dimensional Fund Advisors LP (3.55%), Lazard Asset Management LLC (3.54%) and Victory Capital Management Inc. (3.30%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon. View institutional ownership trends. How do I buy shares of Omnicell? Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings2/06/2025Today3/30/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electronic computers Sub-IndustryHealth Care Technology Current SymbolNASDAQ:OMCL CIK926326 Webwww.omnicell.com Phone(877) 415-9990Fax847-596-3402Employees3,800Year Founded1992Price Target and Rating Average Stock Price Target$51.00 High Stock Price Target$64.00 Low Stock Price Target$36.00 Potential Upside/Downside+45.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.27 Trailing P/E Ratio129.67 Forward P/E Ratio32.12 P/E Growth7.53Net Income$12.53 million Net Margins1.13% Pretax Margin2.30% Return on Equity3.82% Return on Assets2.07% Debt Debt-to-Equity Ratio0.13 Current Ratio1.37 Quick Ratio1.22 Sales & Book Value Annual Sales$1.11 billion Price / Sales1.47 Cash Flow$2.70 per share Price / Cash Flow12.95 Book Value$26.84 per share Price / Book1.30Miscellaneous Outstanding Shares46,759,000Free Float45,094,000Market Cap$1.64 billion OptionableOptionable Beta0.85 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:OMCL) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omnicell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.